Drugs and patents in ATC class J01CA - Penicillins with extended spectrum

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
AMPICILLIN SODIUM	ampicillin sodium
OMNIPEN-N	ampicillin sodium
PENBRITIN-S	ampicillin sodium
>Tradename	>Generic Name

Last updated: June 7, 2026

ATC J01CA covers extended-spectrum penicillins, with the dominant global revenue center being amoxicillin/clavulanate combinations and, in selected markets, other extended-spectrum penicillins (eg, ampicillin/sulbactam is adjacent in many therapeutic decisions though often categorized under other ATC groupings). The near-term patent and exclusivity landscape for J01CA products is shaped less by “new chemical entity” protection and more by (1) formulation and process patents around oral solids and stable liquid compositions, (2) fixed-dose combination IP for the paired β-lactam and β-lactamase inhibitor, (3) pediatric and line-extension exclusivities where applicable, and (4) generic or biosimilar-style competition risk via ANDA submissions and settlement dynamics where the reference product’s last exclusivity and Orange Book-listed patents expire.

Because ATC J01CA is a class label (not a single drug), the patent landscape is inherently product-specific. The market dynamics also differ by route (oral versus IV), inhibitor chemistry, and regional regulatory timing, with the largest exposure tied to well-established amoxicillin/clavulanate franchises where branded products are largely off-patent in many jurisdictions, leaving enforcement to secondary patents and packaging/manufacturing claims.

Which extended-spectrum penicillins fall under ATC J01CA, and how is the market structured?

ATC J01CA is “Penicillins with extended spectrum.” In practice, commercial competition in this space is dominated by extended-spectrum aminopenicillins and their β-lactamase inhibitor combinations, with the bulk of category volume in community-acquired respiratory and skin and soft tissue indications where these combinations remain standard-of-care in multiple guidelines.

What are the main active ingredients and fixed-dose combinations within J01CA?

Key commercial anchors include:

Amoxicillin/clavulanate (oral and IV fixed combinations). This is the core franchise product class across many countries.
Other aminopenicillin-based extended-spectrum penicillins may be used regionally, but the category’s market share and patent enforcement intensity concentrate on the amoxicillin/clavulanate combination universe.

How does the competitive landscape differ by country and route?

Oral markets: generic penetration is high for long-standing tablets/suspensions, leaving fewer first-expiration “patent wins.” Ongoing brand defense tends to rely on secondary patents (particle size, polymorph control, stability, formulation or manufacturing claims) and regulatory exclusivities (where still active for the relevant strength, form, or age-appropriate presentation).
Hospital/IV markets: product substitutions can be slower where formulary decisions, local procurement contracts, and stability/infusion compatibility are decisive. Still, once the primary combination IP expires, generics and authorized generics can scale quickly when tender specifications permit.

What is the revenue exposure concentration within J01CA?

Revenue exposure concentrates in:

the brand-to-generic transition for combination oral products and
inventory and tender cycles for IV formulations. The practical effect for patent strategy is that the “time to generic” is governed by the ability to clear regulatory and quality equivalence for the same dosage forms and strengths, not solely by the chemical composition claims.

What patents protect extended-spectrum penicillins like amoxicillin/clavulanate (composition, formulation, and methods)?

Patent estates for extended-spectrum penicillins typically split into three layers.

Composition of matter: β-lactam + inhibitor chemistry

For fixed-dose combinations, composition claims cover:

the combination as such,
the pharmaceutical composition including the inhibitor,
and sometimes the specific salt forms, ratios, and dosage regimens.

In older franchises, primary composition protection is typically expired in most major markets. The practical enforcement value is in secondary layers.

Formulation and stability patents

Secondary patents often cover:

oral solid formulations (tablet properties, coating systems, disintegration behavior),
suspensions (reconstitution stability, particle size distribution, viscosity targets),
liquid stability (shelf life under heat/light conditions),
solid-state forms (polymorph/rehydrate control if relevant to the β-lactam component),
and excipients and release profiles.

These can delay generic substitution when generics must demonstrate bioequivalence and meet quality specs tied to the patented formulation.

Manufacturing and process patents

Process claims are common where the branded firm controls:

mixing order,
drying/particle engineering steps,
or sterilization/handling procedures for sterile or infusion-ready products.

Process patents can be asserted where generic manufacturers use materially different process steps but where claim scope is broad enough to read on standard approaches for the same dosage form.

Method-of-use and regimen patents

Method-of-use claims are sometimes present for:

dosing regimens,
pediatric dosing strategies,
or expanded indication uses.

For classic antibiotic classes, the legal value of method-of-use protection tends to be lower than formulation IP because many indications are already entrenched and dosing guidelines converge across products.

How strong is the patent estate for extended-spectrum penicillins, and what claim types drive enforceability?

Overall strength in J01CA is usually measured by whether valid, enforceable, and remaining claims exist for a specific dosage form and strength.

What makes enforcement stronger for J01CA products?

Narrow but specific formulation claims tied to stability or release properties can block “workalike” competition if generic product design must copy the patented feature.
Process claims can be enforceable if the patented step is essential and cannot be designed around without materially changing the product.
Combination claims are usually expired for legacy franchises, reducing leverage unless there is an active line extension.

What makes enforcement weaker for J01CA products?

Many older composition patents are expired.
Generics can often design around by switching excipient systems and manufacturing routes.
Courts scrutinize antibiotic method-of-use claims tied to routine clinical regimens, especially where guideline dosing is well established.

When does exclusivity end for extended-spectrum penicillins in the US (Orange Book timelines)?

For US market access, the relevant framework is the FDA Orange Book plus Hatch-Waxman exclusivity and any applicable pediatric exclusivity under FD&C Act 505A. The key market outcome is when:

the reference listed patents expire, and
any exclusivity (3- or 5-year NDA exclusivity; pediatric 6-month extension) ends for the specific reference product.

In legacy J01CA antibiotics, primary composition patents and many listed patents typically do not anchor ongoing exclusivity. Market timing is usually determined by:

last expiration among listed patents tied to the specific dosage form/strength,
and whether a settlement or authorized generic arrangement accelerates or delays entry.

What Orange Book listings and patent expirations should matter for market entry?

Operationally, market entry risk is highest when:

the last listed patent for the relevant strength/dosage form expires soon, and
there is no remaining exclusivity barrier.

Conversely, if Orange Book shows remaining formulation or process patents, generic entry can be delayed or litigated.

Which patent families typically appear in Orange Book for combination antibiotics?

Commonly observed patterns across fixed-dose antibiotic products:

ratio-defined combination composition claims,
oral dosage form compositions (tablet/suspension),
stability-linked patents for reconstitution or shelf life,
and manufacturing process patents for sterile or IV forms.

What is the Paragraph IV and litigation risk for generic entry of J01CA products?

Paragraph IV risk is highest for brands where:

Orange Book lists multiple still-live patents, and
the generic applicant must certify to non-infringement or invalidity.

How do settlements usually affect the J01CA generic launch timeline?

Settlements often:

permit entry on or shortly after a specific patent expiration date,
include design-around obligations or limited product scope (strengths or dosage forms),
and can incorporate a “carve-out” for certain presentations.

Given the long tenure of many J01CA franchises, the settlement landscape in the category tends to be incremental, adjusting launch timing rather than stopping entry indefinitely.

How does amoxicillin/clavulanate patent status drive competitive dynamics and pricing?

Amoxicillin/clavulanate is the main battleground for J01CA category dynamics.

What generic substitution does to pricing and share

Once primary patents expire, competition drives pricing compression.
The strongest residual pricing power often maps to:
- branded convenience formulations (eg, pediatric-friendly suspensions in select markets),
- supply reliability and tender outcomes,
- and any remaining formulation patents that sustain partial exclusivity.

What happens when secondary patents remain

Secondary patents can delay full generic equivalence when they control:

stability,
reconstitution performance,
or specific release behavior tied to quality and shelf life.

This tends to sustain a premium for a narrower subset of branded presentations rather than the whole line.

How do formulation patents impact generic “workalike” entry for extended-spectrum penicillins?

Formulation patents are typically the most relevant barrier once composition-of-matter is expired.

Which formulation features create design-around difficulty?

stability constraints that force specific excipient selection or pH targets,
particle size distribution targets,
coating or disintegration systems that preserve shelf-life or taste acceptance,
IV infusion compatibility, including physiochemical compatibility claims tied to carrier solutions.

Generic applicants can sometimes design around, but doing so can increase development cost and create bioequivalence risk.

What is the market effect when generic substitutes arrive late?

When formulation patents delay launches, pricing stays higher for longer for the affected dosage forms. Where the category is tender-driven, brands with delayed generic access often capture procurement share until a compliant generic is available.

What patent litigation affects extended-spectrum penicillin markets most often?

Litigation in antibiotics categories generally clusters around:

Orange Book-listed patents,
method-of-use or formulation patents tied to a specific presentation,
and process claims asserted against generic manufacturing.

For J01CA, the “center of gravity” usually shifts from primary composition claims (older) to formulation and process claims (ongoing).

What generic entry risks exist for fixed-dose combination penicillins across major markets?

Generic risk is multi-factor:

Regulatory approval timing (ANDA review and inspections),
quality equivalence (bioequivalence for oral, sterility and infusion performance for IV),
patent certification outcomes (Paragraph IV outcomes and injunction risk),
settlement outcomes (authorized generics and licensed entry dates).

Which dosage forms carry the highest entry friction?

pediatric suspensions and liquids with tight stability specs,
IV sterile formulations with infusion stability constraints,
and strengths with formulation-linked patents.

Which companies are most likely to challenge or defend extended-spectrum penicillin IP?

The market typically includes:

originator/branded antibiotic holders and
large generic and specialty generics with strong ANDA pipelines.

For J01CA, the enforcement and challenge ecosystem is usually:

branded holder defending remaining Orange Book patents,
generics filing Paragraph IV certifications against multiple patents,
and settlement players negotiating entry dates by dosage form.

(Company-by-company litigation requires product-level Orange Book and docket-level sources; without product specificity, company mapping would be unreliable.)

How does J01CA compare with other ATC penicillin subclasses in patent and generic dynamics?

Compared with narrower or newer penicillin subclasses:

J01CA’s extended-spectrum penicillins tend to be older and more widely genericized.
The patent estate, where still active, is more likely to be secondary (formulation/process) rather than primary composition.
Market dynamics are more about stability and dose-form constraints than chemical novelty.

This makes competitive outcomes more sensitive to:

dosage form requirements,
shelf-life specifications,
and tender procurement rules.

What timelines typically matter most for J01CA market entry decisions?

For a planning horizon, investors and licensors track:

last listed patent expiration by dosage form/strength,
any remaining exclusivity extension events,
ANDA filing dates (to infer Paragraph IV timing),
and whether settlements shift entry to an agreed date.

Decision-relevant timeline model (generalized)

T0: last live Orange Book patent expiration (by strength and form)
T0 + 0–12 months: generic approval and scale-up
T0 + 12–24 months: full market penetration and pricing normalization

Actual timing varies by market and dosage form.

Key Takeaways

ATC J01CA market dynamics are dominated by extended-spectrum penicillin fixed-dose combinations, led commercially by amoxicillin/clavulanate.
Patent leverage in J01CA typically shifts from primary composition-of-matter to secondary formulation, stability, and manufacturing/process IP.
US exclusivity and Orange Book patent expirations, by specific dosage form and strength, drive generic launch timing more than the ATC class label.
Paragraph IV litigation risk is usually incremental once primary patents expire, often resulting in settlements that calibrate entry dates rather than permanently blocking competition.
Formulation patents create the biggest practical “workalike” barriers because generics must meet stability, reconstitution, and quality requirements tied to those claims.

FAQs

How do formulation patents for amoxicillin/clavulanate affect generic suspension launches?
What Orange Book patent categories most often determine the last effective barrier for fixed-dose combination antibiotics?
How do Paragraph IV settlements typically change the timing of generic entry for antibiotic tablets versus liquids?
What manufacturing process claim types create the highest injunction risk in ANDA litigation for sterile antibiotic products?
How does tender-driven hospital procurement influence post-expiration pricing trajectories in extended-spectrum penicillins?

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
US Code. 35 U.S.C. § 271 and related Hatch-Waxman provisions; 21 U.S.C. § 355.
FDA. Statutes and Regulations: Patent and Exclusivity (Hatch-Waxman Framework). US Food and Drug Administration.

Drugs in ATC Class J01CA

Drugs in ATC Class: J01CA - Penicillins with extended spectrum

Market dynamics and patent landscape for ATC Class J01CA (extended-spectrum penicillins)